Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07303114Recruiting
HIV screening missed in general practice study
This study looks at missed chances for HIV testing in general doctor offices. It focuses on people who were diagnosed with HIV between 2021 and 2024.
StrasbourgAges 18 years+ - NCT07303582RecruitingPhase 4
Freezing nerves to ease pain from muscle tightness
This study tests if freezing specific nerves (cryoneurolysis) can reduce pain caused by muscle tightness (spasticity) after a brain or spinal cord injury, or from multiple sclerosis. It is for people who already get Botox injections for this pain.
OxfordAges 18 years+ - NCT07303790RecruitingEarly Phase 1
Study of GC012F for people with multiple sclerosis
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
Hubei, HubeiAges 18 years+ - NCT07304375Recruiting
Exercise and sleep effects on learning and abilities in MS
This trial tests how combining exercise and sleep monitoring can improve motor learning and daily function in people with early relapsing-remitting multiple sclerosis. It may help you move better and feel more capable in daily life.
CopenhagenAges 18–70 - NCT07304505Recruiting
Probiotics for adults with rheumatoid arthritis
This study tests whether a daily probiotic supplement can help adults with rheumatoid arthritis. You must have a stable RA treatment plan and be willing to take the probiotic for the duration of the study.
Chicago, IllinoisAges 18 years+ - NCT07304856Recruiting
Studying lung involvement in women with LAM or TSC
This trial examines tiny particles called extracellular vesicles from your blood to see if they can help doctors understand lung problems in women with lymphangioleiomyomatosis (LAM) or tuberous sclerosis complex (TSC). It may help find new ways to track the disease without invasive tests.
Milan, MilanoAges 18–80 - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07305337Recruiting
AI health education for blood cancer patients
This trial tests if an artificial intelligence (AI) program can help people with blood cancer learn about their condition and treatment. The goal is to see if AI-assisted education improves their understanding and care.
Wuhan, HubeiAges 18–90 - NCT07305974RecruitingPhase 2
Study of RG002C0106 for primary IgA nephropathy
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07306156RecruitingPhase 1/Phase 2
GP350 CAR-T for Epstein-Barr virus related lymphoma
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Hefei, AnhuiAges 18–70 - NCT07308886RecruitingPhase 2
CYT107 for Kaposi sarcoma in HIV patients with low CD4
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
Bethesda, MarylandAges 18–120 - NCT07309497Recruiting
Geriatric Assessment for Older Adults Before CAR-T or Bispecific Therapy
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
BernAges 65 years+ - NCT07309848Recruiting
Hip fracture surgery timing and blood transfusion risk on DOACs
This study looks at whether the timing of hip fracture surgery affects the need for blood transfusions in patients taking blood thinners (DOACs). It might help guide better care for people on these medications.
AlmeloAges Any age - NCT07309822Recruiting
Beltaven® venom allergy immunotherapy study
This study tests a treatment called Beltaven® for people with severe allergic reactions to bee, wasp, or hornet stings. It aims to see if the treatment is safe and helps prevent future reactions.
Barcelona, BarcelonaAges 14 years+ - NCT07312045Recruiting
Gum health and healing after non-surgical treatment
This study looks at how certain blood and saliva measurements relate to gum disease and healing after a deep cleaning. It may help find better ways to track gum health.
Merkez, ErzincanAges 18–65 - NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+ - NCT07312266Recruiting
Questioning asymptomatic TB in HIV patients
This study looks for tuberculosis (TB) in people with HIV who have no symptoms. It aims to understand how common hidden TB is, which could lead to better detection and prevention.
Manhiça, Maputo ProvinceAges 18 years+ - NCT07312474Recruiting
Study of Anaplasmosis Cases in Alsace
This study looks at people in Alsace, France, who have been diagnosed with anaplasmosis (a tick-borne infection). It aims to understand the disease's patterns and symptoms.
StrasbourgAges 18 years+ - NCT07312630RecruitingEarly Phase 1
A study of LV009 for certain blood cancers
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Hefei, AnhuiAges 18–70 - NCT07313462Recruiting
Comparing treatment strategies for MS starting after age 50
This trial looks at two ways to treat multiple sclerosis (MS) that begins after age 50. It compares starting with a stronger medication right away versus starting with a milder one and then switching if needed.
StrasbourgAges 50 years+ - NCT07313592Recruiting
Genome sequencing study for ALL patients
This study uses whole genome sequencing to analyze your leukemia's DNA. The goal is to find unique genetic changes that may help guide future treatments, though this study does not recommend any specific therapy.
St Louis, MissouriAges Up to 30 years - NCT07313904Recruiting
Fungal exposure and lung health study
This study looks at how environmental fungi (mold) affect lung function and asthma. Researchers need healthy volunteers without lung disease to compare results.
Ningbo, ZhejiangAges 18–80 - NCT07313943Recruiting
Study of PAX5-negative Hodgkin-like lymphomas
This study looks at a rare type of lymphoma that looks like Hodgkin lymphoma but lacks a protein called PAX5. The goal is to better understand and diagnose this condition, which can be hard to tell apart from other lymphomas.
TübingenAges 18 years+ - NCT07313982Recruiting
Leukemia study looking at LEF1 protein levels
This study is examining levels of a protein called LEF1 in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if LEF1 can help predict survival and confirm diagnosis.
Bologna, BOLOGNAAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.